Targeted tissue perfusion versus macrocirculation-guided standard care in patients with septic shock (TARTARE-2S): study protocol and statistical analysis plan for a randomized controlled trial. (Record no. 26290964)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02217 a2200613 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250517110659.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201802s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1745-6215 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1186/s13063-016-1515-x |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Pettilä, Ville |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20180205 |
245 00 - TITLE STATEMENT | |
Title | Targeted tissue perfusion versus macrocirculation-guided standard care in patients with septic shock (TARTARE-2S): study protocol and statistical analysis plan for a randomized controlled trial. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Trials |
Date of publication, distribution, etc. | 08 2016 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 384 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Arterial Pressure |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Biomarkers |
General subdivision | blood |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cardiotonic Agents |
General subdivision | therapeutic use |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cardiovascular Agents |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Clinical Protocols |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Combined Modality Therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Data Interpretation, Statistical |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Europe |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Feasibility Studies |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Fluid Therapy |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Hemodynamics |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Lactic Acid |
General subdivision | blood |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Microcirculation |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Models, Statistical |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Prospective Studies |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Regional Blood Flow |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Renal Replacement Therapy |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Research Design |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Respiration, Artificial |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Sample Size |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Shock, Septic |
General subdivision | diagnosis |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Time Factors |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Treatment Outcome |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Vasoconstrictor Agents |
General subdivision | therapeutic use |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Merz, Tobias |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Wilkman, Erika |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Perner, Anders |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Karlsson, Sari |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Lange, Theis |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Hästbacka, Johanna |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Hjortrup, Peter Buhl |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Kuitunen, Anne |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Jakob, Stephan M |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Takala, Jukka |
773 0# - HOST ITEM ENTRY | |
Title | Trials |
Related parts | vol. 17 |
-- | p. 384 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1186/s13063-016-1515-x">https://doi.org/10.1186/s13063-016-1515-x</a> |
Public note | Available from publisher's website |
No items available.